(MedPage Today) — Novo Nordisk sued rival drugmaker Eli Lilly, alleging false advertising claims about relative weight-loss drug performance. (Reuters via NBC News) GLP-1 drug use surged from 2017 to 2022, jumping 230% in adults with diabetes…
Source: MedPage Today — Headlines
